...
vrca-img

Verrica Pharmaceuticals Inc, Common Stock

VRCA

NMQ

$0.636

-$0.06

(-8.57%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$63.40M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
631.10K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.46
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.67 L
$11.41 H
$0.636

About Verrica Pharmaceuticals Inc, Common Stock

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameVRCASectorS&P500
1-Week Return-26.5%-2.06%-0.55%
1-Month Return-27.58%-1.92%2.72%
3-Month Return-65.24%-10.4%7.66%
6-Month Return-91.96%-4.6%10.15%
1-Year Return-88.43%4.06%27.53%
3-Year Return-93.02%1.94%32.31%
5-Year Return-95.71%36.48%89.2%
10-Year Return-96.33%97.46%194.59%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-12.00M12.00M9.03M5.12M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":75.27,"profit":true},{"date":"2023-12-31","value":42.7,"profit":true}]
Cost of Revenue257.20K229.00K472.00K725.00K746.00K[{"date":"2019-12-31","value":34.48,"profit":true},{"date":"2020-12-31","value":30.7,"profit":true},{"date":"2021-12-31","value":63.27,"profit":true},{"date":"2022-12-31","value":97.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(257.20K)(229.00K)11.53M8.31M4.38M[{"date":"2019-12-31","value":-2.23,"profit":false},{"date":"2020-12-31","value":-1.99,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":72.06,"profit":true},{"date":"2023-12-31","value":37.98,"profit":true}]
Gross Margin-(1.91%)96.07%91.97%85.44%[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1.99,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.74,"profit":true},{"date":"2023-12-31","value":88.94,"profit":true}]
Operating Expenses30.08M40.18M42.91M29.60M70.14M[{"date":"2019-12-31","value":42.89,"profit":true},{"date":"2020-12-31","value":57.29,"profit":true},{"date":"2021-12-31","value":61.18,"profit":true},{"date":"2022-12-31","value":42.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(30.08M)(40.18M)(30.91M)(21.30M)(65.76M)[{"date":"2019-12-31","value":-3008000000,"profit":false},{"date":"2020-12-31","value":-4018100000,"profit":false},{"date":"2021-12-31","value":-3090800000,"profit":false},{"date":"2022-12-31","value":-2129600000,"profit":false},{"date":"2023-12-31","value":-6575900000,"profit":false}]
Total Non-Operating Income/Expense3.75M(5.03M)(8.34M)(4.89M)(659.00K)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-134,"profit":false},{"date":"2021-12-31","value":-222.51,"profit":false},{"date":"2022-12-31","value":-130.32,"profit":false},{"date":"2023-12-31","value":-17.57,"profit":false}]
Pre-Tax Income(28.21M)(42.69M)(35.08M)(24.49M)(67.00M)[{"date":"2019-12-31","value":-2820700000,"profit":false},{"date":"2020-12-31","value":-4269400000,"profit":false},{"date":"2021-12-31","value":-3508000000,"profit":false},{"date":"2022-12-31","value":-2448700000,"profit":false},{"date":"2023-12-31","value":-6699500000,"profit":false}]
Income Taxes(257.00K)2.80M3.82M3.19M668.11K[{"date":"2019-12-31","value":-6.72,"profit":false},{"date":"2020-12-31","value":73.32,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":83.47,"profit":true},{"date":"2023-12-31","value":17.48,"profit":true}]
Income After Taxes(27.95M)(45.50M)(38.90M)(27.68M)(67.66M)[{"date":"2019-12-31","value":-2795000000,"profit":false},{"date":"2020-12-31","value":-4549700000,"profit":false},{"date":"2021-12-31","value":-3890300000,"profit":false},{"date":"2022-12-31","value":-2767800000,"profit":false},{"date":"2023-12-31","value":-6766310500,"profit":false}]
Income From Continuous Operations(28.21M)(42.69M)(35.08M)(24.49M)(48.31M)[{"date":"2019-12-31","value":-2820700000,"profit":false},{"date":"2020-12-31","value":-4269400000,"profit":false},{"date":"2021-12-31","value":-3508000000,"profit":false},{"date":"2022-12-31","value":-2448700000,"profit":false},{"date":"2023-12-31","value":-4831300000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(27.95M)(45.50M)(38.90M)(27.68M)(67.00M)[{"date":"2019-12-31","value":-2795000000,"profit":false},{"date":"2020-12-31","value":-4549700000,"profit":false},{"date":"2021-12-31","value":-3890300000,"profit":false},{"date":"2022-12-31","value":-2767800000,"profit":false},{"date":"2023-12-31","value":-6699500000,"profit":false}]
EPS (Diluted)(1.13)(1.71)(1.29)(0.79)(1.46)[{"date":"2019-12-31","value":-113,"profit":false},{"date":"2020-12-31","value":-171,"profit":false},{"date":"2021-12-31","value":-129,"profit":false},{"date":"2022-12-31","value":-79,"profit":false},{"date":"2023-12-31","value":-146,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

VRCA
Cash Ratio 1.09
Current Ratio 1.34
Quick Ratio 1.22

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

VRCA
ROA (LTM) -71.41%
ROE (LTM) -2059.89%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

VRCA
Debt Ratio Lower is generally better. Negative is bad. 2.03
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -1.03

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

VRCA
Trailing PE NM
Forward PE NM
P/S (TTM) 6.88
P/B 238.54
Price/FCF NM
EV/R 9.68
EV/Ebitda NM

FAQs

What is Verrica Pharmaceuticals Inc share price today?

Verrica Pharmaceuticals Inc (VRCA) share price today is $0.636

Can Indians buy Verrica Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Verrica Pharmaceuticals Inc (VRCA) on Vested. To buy Verrica Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VRCA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Verrica Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Verrica Pharmaceuticals Inc (VRCA) via the Vested app. You can start investing in Verrica Pharmaceuticals Inc (VRCA) with a minimum investment of $1.

How to invest in Verrica Pharmaceuticals Inc shares from India?

You can invest in shares of Verrica Pharmaceuticals Inc (VRCA) via Vested in three simple steps:

  • Click on Sign Up or Invest in VRCA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Verrica Pharmaceuticals Inc shares
What is Verrica Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Verrica Pharmaceuticals Inc (VRCA) is $11.41. The 52-week low price of Verrica Pharmaceuticals Inc (VRCA) is $0.67.

What is Verrica Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Verrica Pharmaceuticals Inc (VRCA) is

What is Verrica Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Verrica Pharmaceuticals Inc (VRCA) is 238.54

What is Verrica Pharmaceuticals Inc dividend yield?

The dividend yield of Verrica Pharmaceuticals Inc (VRCA) is 0.00%

What is the Market Cap of Verrica Pharmaceuticals Inc?

The market capitalization of Verrica Pharmaceuticals Inc (VRCA) is $63.40M

What is Verrica Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Verrica Pharmaceuticals Inc is VRCA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top